xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

361

ICAR SINONASAL TUMORS

TABLE XXXII.3 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Temporal lobe RT necrosis

1. Temporal lobe RT necrosis occurred in 6% of patients and was grade 3 + in 1% of patients 2. Risk of temporal lobe RT necrosis was correlated with the volume of temporal lobe receiving high doses of RT 1. All patients were treated surgically, and 38% were also treated medically (with HBO, antibiotics, and/or dressing changes) prior to surgery 2. 23 patients were treated with free flaps and eight with primary closure 3. Recurrence was seen in 14% of patients treated with a free flap versus 50% with primary closure 4. Ongoing cancer treatment ( p = 0.02) was associated with increased recurrence risk inclusion in the RT field, and anemia were associated with increased ORN odds Patients receiving proton therapy had lower opiate requirement and lower gastrostomy tube dependence compared to those receiving IMRT 1. Acutely, 26% of patients experienced grade 3 mucositis, 38% of patients experienced AEs of the ear, and 89% of patients reported loss of taste 2. The most common late AEs were grade 1 xerostomia, hearing impairment, and ocular toxicity 1. The 3-year incidence of RT necrosis was 12.4%, and 5.7% for grade 2 or higher 2. Median time to development was 21 months 3. A higher volume of temporal lobe receiving > 60GyRTwas associated with increased odds of developing temporal lobe RT necrosis

Kitpanit

2020 3

Retrospective cohort

234 patients with head and neck cancer receiving proton therapy to the skull base

et al. 2151

Habib et al. 2162

2020 3

Retrospective cohort

31 patients with skull base ORN following skull base surgery andRT

1. Treatment modality 2. Treatment outcomes 3. Predictors of recurrence

Hanet al. 2153

Skull base ORN 1. Skull base ORN occurred in 1% of patients at a mean latency of 46months 2. T stage, total RT dose to the nasopharynx, skull base

2018 3

Retrospective cohort

1348 patients with NPC treated with external beamRT

McDonald et al. 2149

2016 3

Retrospective cohort

Patients with

Opiate pain

sinonasal, nasal cavity, or nasopharyngeal cancer receiving protonRT( n = 14) or IMRT( n = 26) paranasal sinus) with malignant salivary gland tumors of the head and neck treated with IMRT and dose-escalated carbon ion therapy with proton therapy for skull base chordoma, chondrosarcoma, ACC, or SNM

medication requirement and gastrostomy tube dependence

Jensen et al. 550

AEs

2015 3

Prospective cohort

53 patients (34%

McDonald et al. 2150

2015 3

Retrospective cohort

66 patients treated

Temporal lobe RT necrosis

(Continues)